Article Text

Download PDFPDF
Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE”
  1. Guillermo J Pons-Estel1,
  2. Manuel F. Ugarte-Gil2,3,
  3. Guillermina B Harvey4,
  4. Bernardo A Pons-Estel1,
  5. Graciela S Alarcón5,6
  1. 1 Departament of Rheumatology, Grupo Oroño-Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina
  2. 2 Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru
  3. 3 Universidad Científica del Sur, Lima, Peru
  4. 4 Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina
  5. 5 Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA
  6. 6 Department of Medicine, School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru
  1. Correspondence to Dr Guillermo J Pons-Estel, Departament of Rheumatology, Grupo Oroño-Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina; gponsestel{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the report by Whittall Garcia et al 1 on ominosity, a proxy for the threatening role of the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Systemic Lupus Erythematosus (SLE) Classification Criteria Score; in this article, the authors propose that a score of ≥20 predicts disease severity within 5 years of disease diagnosis. We would like to congratulate the authors for their novel approach in using these criteria as predictors. In their study, the authors included two cohorts: (1) a single-centre inception cohort that included 867 patients with SLE with a mean disease duration, from diagnosis to the first visit of 0.2 years in which they developed the concept, and (2) a validation cohort that included 807 patients from the multiethnic, multinational Systemic Lupus International …

View Full Text


  • Twitter @gponsestel

  • Contributors All the authors contributed to the concept and writing of this letter.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles